The PHOSP-COVID study has been awarded £8.4million jointly by UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR).
This study is one of a number of #COVID-19 studies that have been given urgent public health research status by the Department of Health and Social Care.
Gisli Jenkins, of the NIHR Nottingham Biomedical Research Centre and Professor of Experimental Medicine in the School of Medicine at the University of Nottingham, will share expertise with a national consortium of leading researchers and clinicians from across the UK to assess the impact of #COVID-19 on patients’ health and their recovery.
Around 10,000 patients are expected to take part in the study led by the NIHR Leicester Biomedical Research Centre – a partnership of the University of Leicester and University Hospitals of Leicester NHS Trust, making it one of the largest comprehensive studies in the world to understand and improve the health of survivors after hospitalisation from #COVID-19.
The PHOSP-COVID study is widely supported across the NIHR infrastructure, including the Translational Research Collaborations for respiratory, mental health, cardiovascular, dementia, and diet, exercise and nutrition, and many of the NIHR Biomedical Research Centres, which are set up to translate lab-based scientific breakthroughs into potential new treatments, diagnostics and medical technologies.